Logo
x

Search

Subscribe Now

seven

Takeda and Neurocrine Collaborate for Seven Neuro Programs Worth Up to $2B

Takeda and Neurocrine Collaborate for Seven Neuro Programs Worth Up to $2B

  • June 17, 2020
STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe

STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe

  • November 7, 2019
Takeda and Neurocrine Collaborate for Seven Neuro Programs Worth Up to $2B

    Takeda and Neurocrine Collaborate for Seven Neuro Programs Worth Up to $2B

    • June 17, 2020
    PharmaShots Weekly Snapshot (March 02-06, 2020)

      PharmaShots Weekly Snapshot (March 02-06, 2020)

      • March 9, 2020
      Gilead to Acquire Forty Seven for $4.9B

        Gilead to Acquire Forty Seven for $4.9B

        • March 2, 2020
        PharmaShots Weekly Snapshot (November 11-15, 2019)

          PharmaShots Weekly Snapshot (November 11-15, 2019)

          • November 18, 2019
          STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe

            STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe

            • November 7, 2019
            Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven to Develop and Commercialize 5F9 in Selected Asian Countries

              Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven to Develop and Commercialize 5F9 in Selected Asian Countr...

              • July 12, 2019
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.